405 related articles for article (PubMed ID: 25878334)
21. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.
Mehnert JM; Panda A; Zhong H; Hirshfield K; Damare S; Lane K; Sokol L; Stein MN; Rodriguez-Rodriquez L; Kaufman HL; Ali S; Ross JS; Pavlick DC; Bhanot G; White EP; DiPaola RS; Lovell A; Cheng J; Ganesan S
J Clin Invest; 2016 Jun; 126(6):2334-40. PubMed ID: 27159395
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer.
Song Z; Cheng G; Xu C; Wang W; Shao Y; Zhang Y
Lung Cancer; 2018 Apr; 118():57-61. PubMed ID: 29572003
[TBL] [Abstract][Full Text] [Related]
23.
van Gool IC; Bosse T; Church DN
Oncoimmunology; 2016 Mar; 5(3):e1072675. PubMed ID: 27141333
[TBL] [Abstract][Full Text] [Related]
24. Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability.
Haruma T; Nagasaka T; Nakamura K; Haraga J; Nyuya A; Nishida T; Goel A; Masuyama H; Hiramatsu Y
PLoS One; 2018; 13(4):e0195655. PubMed ID: 29659608
[TBL] [Abstract][Full Text] [Related]
25. The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis.
Jumaah AS; Al-Haddad HS; McAllister KA; Yasseen AA
PLoS One; 2022; 17(2):e0263585. PubMed ID: 35139130
[TBL] [Abstract][Full Text] [Related]
26. The more tumors change, the more they stay tame: do T cells keep POLE ultramutated endometrial carcinomas in check?
Nelson BH; McAlpine JN
Gynecol Oncol; 2015 Jul; 138(1):1-2. PubMed ID: 26072691
[No Abstract] [Full Text] [Related]
27. The P286R mutation of DNA polymerase ε activates cancer-cell-intrinsic immunity and suppresses endometrial tumorigenesis via the cGAS-STING pathway.
Tang M; Yin S; Zeng H; Huang A; Huang Y; Hu Z; Shah AR; Zhang S; Li H; Chen G
Cell Death Dis; 2024 Jan; 15(1):69. PubMed ID: 38238314
[TBL] [Abstract][Full Text] [Related]
28. POLE mutation combined with microcystic, elongated and fragmented (MELF) pattern invasion in endometrial carcinomas might be associated with poor survival in Chinese women.
He D; Wang H; Dong Y; Zhang Y; Zhao J; Lv C; Zheng X; Li D; Li T
Gynecol Oncol; 2020 Oct; 159(1):36-42. PubMed ID: 32800323
[TBL] [Abstract][Full Text] [Related]
29. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.
Bosse T; Nout RA; McAlpine JN; McConechy MK; Britton H; Hussein YR; Gonzalez C; Ganesan R; Steele JC; Harrison BT; Oliva E; Vidal A; Matias-Guiu X; Abu-Rustum NR; Levine DA; Gilks CB; Soslow RA
Am J Surg Pathol; 2018 May; 42(5):561-568. PubMed ID: 29505428
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis.
McAlpine JN; Chiu DS; Nout RA; Church DN; Schmidt P; Lam S; Leung S; Bellone S; Wong A; Brucker SY; Lee CH; Clarke BA; Huntsman DG; Bernardini MQ; Ngeow J; Santin AD; Goodfellow P; Levine DA; Köbel M; Kommoss S; Bosse T; Gilks CB; Talhouk A
Cancer; 2021 Jul; 127(14):2409-2422. PubMed ID: 33793971
[TBL] [Abstract][Full Text] [Related]
31. High polymerase ε expression associated with increased CD8+T cells improves survival in patients with non-small cell lung cancer.
Min KW; Kim WS; Kim DH; Son BK; Oh YH; Kwon MJ; Lee HS; Lee SE; Kim IA; Moon JY; Kim KY; Park JH
PLoS One; 2020; 15(5):e0233066. PubMed ID: 32433714
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological characteristics and prognostic value of POLE mutations in endometrial cancer: A systematic review and meta-analysis.
He Y; Wang T; Li N; Yang B; Hu Y
Medicine (Baltimore); 2020 Feb; 99(8):e19281. PubMed ID: 32080141
[TBL] [Abstract][Full Text] [Related]
33. Mutational processes of distinct POLE exonuclease domain mutants drive an enrichment of a specific TP53 mutation in colorectal cancer.
Fang H; Barbour JA; Poulos RC; Katainen R; Aaltonen LA; Wong JWH
PLoS Genet; 2020 Feb; 16(2):e1008572. PubMed ID: 32012149
[TBL] [Abstract][Full Text] [Related]
34. Utility of a custom designed next generation DNA sequencing gene panel to molecularly classify endometrial cancers according to The Cancer Genome Atlas subgroups.
Miller EM; Patterson NE; Gressel GM; Karabakhtsian RG; Bejerano-Sagie M; Ravi N; Maslov A; Quispe-Tintaya W; Wang T; Lin J; Smith HO; Goldberg GL; Kuo DYS; Montagna C
BMC Med Genomics; 2020 Nov; 13(1):179. PubMed ID: 33256706
[TBL] [Abstract][Full Text] [Related]
35. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
[TBL] [Abstract][Full Text] [Related]
36. Phenotype of POLE-mutated endometrial cancer.
Imboden S; Nastic D; Ghaderi M; Rydberg F; Rau TT; Mueller MD; Epstein E; Carlson JW
PLoS One; 2019; 14(3):e0214318. PubMed ID: 30917185
[TBL] [Abstract][Full Text] [Related]
37. Mutant POLQ and POLZ/REV3L DNA polymerases may contribute to the favorable survival of patients with tumors with POLE mutations outside the exonuclease domain.
Huang F; Tanaka H; Knudsen BS; Rutgers JK
BMC Med Genet; 2020 Aug; 21(1):167. PubMed ID: 32838755
[TBL] [Abstract][Full Text] [Related]
38. DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity.
Castellucci E; He T; Goldstein DY; Halmos B; Chuy J
Oncologist; 2017 May; 22(5):497-502. PubMed ID: 28465371
[TBL] [Abstract][Full Text] [Related]
39. PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon.
Rousseau B; Bieche I; Pasmant E; Hamzaoui N; Leulliot N; Michon L; de Reynies A; Attignon V; Foote MB; Masliah-Planchon J; Svrcek M; Cohen R; Simmet V; Augereau P; Malka D; Hollebecque A; Pouessel D; Gomez-Roca C; Guimbaud R; Bruyas A; Guillet M; Grob JJ; Duluc M; Cousin S; de la Fouchardiere C; Flechon A; Rolland F; Hiret S; Saada-Bouzid E; Bouche O; Andre T; Pannier D; El Hajbi F; Oudard S; Tournigand C; Soria JC; Champiat S; Gerber DG; Stephens D; Lamendola-Essel MF; Maron SB; Diplas BH; Argiles G; Krishnan AR; Tabone-Eglinger S; Ferrari A; Segal NH; Cercek A; Hoog-Labouret N; Legrand F; Simon C; Lamrani-Ghaouti A; Diaz LA; Saintigny P; Chevret S; Marabelle A
Cancer Discov; 2022 Jun; 12(6):1435-1448. PubMed ID: 35398880
[TBL] [Abstract][Full Text] [Related]
40. Endometrial cancer with a POLE mutation progresses frequently through the type I pathway despite its high-grade endometrioid morphology: a cohort study at a single institution in Japan.
Monsur M; Yamaguchi M; Tashiro H; Yoshinobu K; Saito F; Erdenebaatar C; Li C; Iwagoi Y; Ohba T; Iyama KI; Katabuchi H
Med Mol Morphol; 2021 Jun; 54(2):133-145. PubMed ID: 33399963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
